In vitro Diagnostics Market

In vitro Diagnostics Market by Product and Service (Instrument, Kits), Technology (Immunoassay, MDx, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) End User (Hospitals) - Global Forecasts ( 2022 - 2026 )

Report Code: MD 3609 Mar, 2022, by marketsandmarkets.com

[426 Pages Report] The global in vitro diagnostics market is projected to reach USD 113.1 billion by 2026 from USD 98.2 billion in 2021, at a CAGR of 2.9% during the forecast period. The growth of the IVD market is mainly driven by the rising geriatric population and the subsequent growth in the prevalence of chronic and infectious diseases, increasing adoption of fully automated and POC instruments in developed regions, growing awareness regarding diseases diagnosis in developing regions, and growing R&D investments by industry players to launch new IVD products. Also, the development of disease-specific markers and tests is expected to offer potential growth opportunities to market players in the coming years. However, the unfavorable reimbursement scenario is expected to restrain the growth of this market during the forecast period.
Global IVD Market Trends

In-Vitro Diagnostics Market

To know about the assumptions considered for the study, Request for Free Sample Report

Impact of Covid-19 on IVD Market

In an optimistic scenario, the COVID-19 pandemic has positively impacted the IVD market. Because of the pandemic, there was an increase in the demand for immunodiagnostics and molecular testing, which was regarded as the gold standard for diagnosing infectious diseases, leading to the increased sales of related consumables and kits. The volume of point-of-care (POC) testing had risen during the COVID-19 pandemic in response to demand for faster on-site screening. During the pandemic era, revenue growth for key players was majorly driven by the sales of COVID-19 diagnostic tests.

In a pessimistic scenario, it could be assumed that the COVID-19 pandemic has lowered the demand for in vitro diagnostics used in specialties such as cardiology, oncology, nephrology, and autoimmune disorders. The footfall in most hospitals, clinics, and community health centers was limited to COVID-19 infection cases and emergency care due to infection control measures and nationwide lockdowns. This has resulted in most major players functioning at negligible capacity for these segments as most of the resources and production capabilities were directed towards manufacturing COVID-19 related products. Therefore, there was a decline in the revenues generated by these segments.

In a realistic scenario, it could be assumed that there was a mixed impact of COVID-19. There was a significant increase in sales of immunodiagnostics and molecular diagnostic products during Q1 2020–Q1 2021. As demand for components used in molecular assays increased, leading manufacturers, particularly those in China, increased their production capacity to meet the needs. As a result, China accounted for between 70-90% of the global capacity for major molecular-assay components, making China the leading global supplier for diagnostics in the pandemic era. The graphs below represent the impact of the pandemic on the revenues of two leading players, Roche Diagnostics and Abbott Laboratories, on their diagnostics business. Both companies experienced a tremendous increase in the revenue generated by the molecular diagnostic segment brought by the increasing use of RT-PCR-based assays that were regarded as the optimal confirmatory tests for viral infections. However, in certain regions of the world, immunoassays dominated the testing scenario because of a shortage of laboratory capacity for molecular assays.

IVD Market Dynamics:

DRIVERS: Shift from centralized to point-of-care testing

The dominant model of laboratory testing throughout the world remains the centralized laboratory that uses automated analytical testing methods to detect target analytes. This trend is well established in clinical chemistry and hematology disciplines and is now extending to other areas, including immunoassays and molecular diagnostics.

Point-of-care devices offer advantages over conventional diagnostic procedures in affordability and ease of use and yield rapid results required for initiating decision-making. The increased adoption of POCT devices is greatly influenced by the need to make healthcare more patient-centered by organizing healthcare services around the patient than the provider. Centralized testing does not represent a convenient process for many patients because the testing process is often disconnected from the consultation. This happens particularly to those patients with a chronic disease such as diabetes who require regular monitoring, including frequent blood tests. The growth in self-monitoring of blood glucose, which is by far the largest segment of POC testing, is in part a testament to this need for more convenient and effective care.

The volume of testing performed outside the conventional laboratory is likely to increase in the coming years, driven by the need to deliver care closer to the patient. The menu of tests performed using POC testing devices has expanded considerably in the last two decades. This development was majorly driven by well-established technologies such as lateral flow strips, immunosensors, and the continual miniaturization of electronics & increased computing power of devices.

Changing technological landscape

The IVD market is characterized by intensive competitiveness. The technological landscape of this market is changing rapidly with automation, AI, and advanced data analytics as players seek to sustain their presence and drive R&D and innovation.

Companies have now started introducing automation in diagnostic tests to meet the changing demand for diagnostics for providers such as clinical laboratories and POC diagnostic centers. The emergence of rapid POC technologies enabled facilities to optimize workflows and decreased labor requirements to process a higher sample load. For instance, due to the large-scale infection and strong transmissibility of COVID-19, high-throughput sequencing tools and automatic lab capacity became key factors of rapid diagnosis. Diagnostic testing and laboratory companies have come together to support public health responses to the pandemic, open data for testing, and create new transformative diagnostic technologies.

RESTRAINTS: Unfavorable reimbursement scenario

The Patient Protection and Affordable Care Act of 2010 changed the dynamics of healthcare delivery and financing in the US; other countries are also experiencing challenges within financing systems, given the number of constant technological evolutions in medicine. In the US, Medicare revised its reimbursement mechanism for some in vitro diagnostic tests, including molecular diagnostic tests, a few years back. Some of these molecular pathology tests do not have their own Healthcare Common Procedure Coding System (HCPCS) codes and are instead billed using unlisted codes. In such cases, Medicare Administrative Contractors (MACs) establish a payment amount for their local jurisdictions. According to CMS, approximately 75% of tests showed reductions in reimbursement rate from January 2017. These tests include molecular diagnostic tests, targeted NGS analysis panels, and tests to detect cancer. These changes in the reimbursement mechanism are expected to adversely affect the US molecular and genetic testing market, which will hinder the growth of the IVD market.

OPPORTUNITY: Development of disease-specific biomarkers and tests

Biomarkers have gained significant clinical value and interest in the medical industry, as they are very useful in the screening, diagnosis, and treatment of diseases. In the diagnosis process, markers can determine staging, grading, and selection of the initial therapy. They monitor therapy, select additional therapies, or monitor recurrent diseases during treatments. Technological advancements in genomics, proteomics, and molecular pathology have helped introduce disease-specific biomarkers with potential clinical value.

The integration of biomarkers and the availability of biomolecular tools are expected to help develop a new range of condition-specific tests, thus creating new opportunities for the IVD market. The discovery of new biomarkers to diagnose various diseases, especially cancer, has brought about revolutionary changes in medicine. Advances in sequencing technology and a better understanding of genomics have increased the efficiency of biomarkers in disease detection. This, in turn, is increasing the demand for precision medicine and is expected to offer significant growth opportunities for market players.

Growing significance of companion diagnostics

Companion diagnostics include tests or assays intended to assist healthcare providers in making treatment decisions for patients based on the best response to therapy. The co-development of companion diagnostics with therapeutic products can significantly alter the drug development process and commercialize drug candidates by yielding safer drugs with enhanced therapeutic efficacy quickly and cost-effectively. With the increased demand for high-priced specialist therapies and safer drugs, the market for companion diagnostics has high growth potential. The growing importance of companion diagnostics also provides growth opportunities for the diagnostics segment and, in turn, the IVD market.

Pharmaceutical companies are increasingly collaborating with diagnostic companies to make safer and more effective drugs. For instance, in September 2021, Thermo Fisher Scientific’s clinical sequencing business and AstraZeneca entered into an agreement to co-develop NGS-based companion diagnostics (CDx) to support AstraZeneca’s expanding portfolio of targeted therapies. Similarly, in January 2021, Illumina Inc. (US) conducted a series of oncology partnerships to expand the reach of its comprehensive genomic profiling family of products, TruSight Oncology.

CHALLENGES: Changing regulatory landscape in the EU

IVD devices are among the most highly regulated products made and marketed globally. The European Union (EU) published two new sets of regulations in the Official Journal, May 2017:

  • Regulation (EU) 2017/745 relating to medical devices (MDs); and
  • Regulation (EU) 2017/746 relating to in vitro diagnostic medical devices (IVDs)

The implementation of the In Vitro Diagnostic Medical Devices Regulations (IVDR) dramatically changes the regulatory landscape for IVD medical devices in the European Union. Some of the biggest changes include an expanded definition of IVDs that includes companion diagnostics and software, a new classification of IVDs, the requirement of Unique Device Identification (UDI) on each device, an expansion of the Quality Management System, and the increased need for Notified Body (NB) review.

The IVDR presents a significant change to the IVD industry because it requires a critical change in technical documentation and quality management. It will also impact the role of economic operators. Manufacturers have often launched in Europe before the US; however, the IVDR made requirements stricter and approval timelines longer, which may change product launch patterns. With new regulations, a huge amount of work will be required to transition from the IVDD to the IVDR. IVDR is more complex and detailed and will require more resources to maintain and implement for IVD manufacturers, thereby posing a challenge to the growth of the IVD market.

  • Operational barriers faced in conducting diagnostic tests

Clinical laboratories across major markets are still evolving; technicians face operational challenges in ensuring effective sample procurement, storage, and transportation, especially while adopting novel technologies such as NGS and lab-on-a-chip PCR devices. Laboratory space also needs to be reconfigured to meet the requirements of conducting specific diagnostic tests used for pathogen detection as a means of avoiding cross-contamination and ensuring efficient time management. This results in considerable cost escalation to maintain and operate advanced molecular diagnostic instruments, particularly those capable of handling a single sample type.

Furthermore, due to the rapid mutation of microbes and the increasing outbreak of epidemics, clinical laboratories need to adopt innovative technologies capable of rapid sample diagnosis. However, the shortage of skilled laboratory technicians to operate advanced diagnostic products has hindered their overall adoption, particularly in emerging markets. In addition, a reluctance to move from manual operations towards automation is another challenge for market growth. Many providers find it difficult to transition to IT-based approaches from manual or traditional approaches or may not prefer to make the shift at all.

“Reagents & kits segment accounted for the largest share in the IVD market.”

Based on product and service, the IVD market is segmented into reagents & kits, instruments, services, and data management software. The reagents & kits segment accounted for the largest share of 68.1% of the IVD market in 2020. Accessibility to a wide range of reagents and the need for reliable, specific, and faster detection of chronic diseases and genetic disorders in the early stages are expected to drive the growth of this segment.

“Oncology segment is expected to witness the fastest growth in the forecast period.”

Based on application, the IVD market is segmented into infectious diseases, diabetes, Oncology, cardiology, drug testing/ pharmacogenomics, HIV/AIDS, autoimmune diseases, nephrology and other applications. In 2020, infectious diseases accounted for 34.1% of the IVD market. The large share of this segment can be attributed to the rising prevalence of infectious diseases and multi-drug-resistant infectious diseases and the growing need for effective diagnostic tools for these diseases. However, the oncology segment is projected to grow at the highest CAGR of 6.6% during the forecast period. The increasing number of cancer cases across the globe, the growing demand for personalized medicine, and the availability of funding for cancer research are the major factors driving the market growth.

“Immunoassay/immunochemistry account for the largest share in the IVD market.”

Based on technology, the IVD market is segmented into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation and hemostasis, urinalysis and other technologies. The immunoassay/immunochemistry segment accounted for 31% of the IVD technologies market in 2020. The growing preference for these technologies in clinical diagnostics over conventional methods and the ability of immunoassay/immunochemistry technologies to offer faster results with high sensitivity and accuracy are contributing to the growth of this market segment.

“Hospital laboratories accounted for the largest share of IVD market in 2020”

Based on the end user, the IVD market is segmented into hospital laboratories, clinical laboratories, academic institutes, POC (point-of-care) testing centers, patients, and other end users. In 2020, hospital laboratories accounted for the largest share of 47% of the IVD market, followed by clinical laboratories (23.8%) and POC testing centers (13%). Many diagnostic tests are carried out in hospitals. The acquisition of smaller physician practices and groups by hospitals is becoming a noticeable trend in the US healthcare industry; the continuation of this trend will support the IVD market for hospital laboratories.

“North America accounted for the largest share of the IVD  market in 2020”

The IVD market is divided into five major regions—North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of 39.8% of the IVD market, followed by Europe (28%), Asia Pacific (22.9%), Latin America (6.5%), and the Middle East & Africa (2.9%). The IVD market in North America is well established, with the US being the major market in this region. Growth in the North American market is mainly driven by the increasing per capita healthcare expenditure and technologically advanced healthcare infrastructure in the region. Initiatives taken by different government associations are also anticipated to boost market growth in the coming years.

Geographic Snapshot: IVD Market

In-Vitro Diagnostics Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key Market Players :

Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), Abbott (US), and Thermo Fisher Scientific (US) are the leading players in this market. Other players in this market are Johnson & Johnson (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Sysmex Corporation (Japan), bioMérieux (France), DiaSorin (Italy), Ortho Clinical Diagnostics (US), and QIAGEN N.V. (Netherlands).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

:

Report Metric

Details

Market Size Available for Years

2019–2026

Base Year Considered

2020

Forecast Period

2021–2026

Forecast Unit

Value (USD Billion)

Segments Covered

By Product and Service, By Technology, By application, By end user

Countries Covered

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East and Africa
    • Saudi Arabia
    • Rest of MEA

The research report categorizes IVD market into the following segments and sub-segments:

By Product and Service

  • Reagents & Kits
  • Instruments
  • Services
  • Data Management Software

By Technology

  • Immunoassay/ Immunochemistry
  • Clinical chemistry
  • Molecular diagnostics
  • Hematology
  • Microbiology
  • Coagulation and Hemostasis
  • Urinalysis
  • Other Technologies

By Application

  • Infectious diseases
  • Diabetes
  • Oncology
  • Cardiology
  • Drug Testing/ Pharmacogenomics
  • Autoimmune diseases
  • HIV/AIDS
  • Nephrology
  • Other applications

By End User

  • Hospital laboratories
  • Clinical laboratories
  • Point-of-care testing centers
  • Academic institutes
  • Patients
  • Other end users

By Country

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Australia
    • Japan
    • India
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East and Africa
    • Turkey
    • Rest of MEA

Recent Developments:

  • In January 2022, Roche Diagnostics (Switzerland) launched cobas pulse system, a blood glucose management solution with mobile digital health capabilities to improve patient care.
  • In September 2021, Abbott Laboratories (US) received US FDA has clearance for the Freestyle libre 2 iOS application for use with compatible iPhones
  • In March 2021, Siemens Healthineers renewed its long-standing supply, distributorship, sales, and service agreement for hemostasis, including a multi-year extension with Sysmex Corporation (Japan).
  • In January 2021, Sysmex Corporation (Japan) entered into a partnership with Roche Diagnostics (Switzerland) to maximize its strengths including competitive products and services and extensive sales and service networks.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 42)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE
          FIGURE 1 IN VITRO DIAGNOSTICS MARKET SEGMENTATION
          FIGURE 2 IN VITRO DIAGNOSTICS MARKET, BY GEOGRAPHY
    1.4 YEARS CONSIDERED FOR THE STUDY
    1.5 CURRENCY
          TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD
    1.6 LIMITATIONS
    1.7 STAKEHOLDERS
    1.8 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 47)
    2.1 RESEARCH APPROACH
          FIGURE 3 RESEARCH DESIGN
           2.1.1 SECONDARY RESEARCH
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY RESEARCH
           2.1.3 PRIMARY SOURCES
                    FIGURE 4 KEY DATA FROM PRIMARY SOURCES
                    FIGURE 5 KEY INDUSTRY INSIGHTS
                    FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                    FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
                    FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY END USER, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION
          FIGURE 10 REVENUE SHARE ANALYSIS ILLUSTRATION: ROCHE DIAGNOSTICS (2020)
          FIGURE 11 SUPPLY-SIDE ANALYSIS: IN VITRO DIAGNOSTICS MARKET (2020)
          FIGURE 13 CAGR PROJECTIONS FROM THE ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES OF THE IVD INDUSTRY (2021-2026)
          FIGURE 14 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF THE IN VITRO DIAGNOSTICS MARKET
    2.3 DATA TRIANGULATION APPROACH
    2.4 MARKET SHARE ESTIMATION
    2.5 ASSUMPTIONS FOR THE STUDY
    2.6 LIMITATIONS
           2.6.1 METHODOLOGY-RELATED LIMITATIONS
           2.6.2 SCOPE-RELATED LIMITATIONS
    2.7 RISK ASSESSMENT
          TABLE 2 RISK ASSESSMENT: IN VITRO DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY (Page No. - 62)

4 PREMIUM INSIGHTS (Page No. - 66)
    4.1 IN VITRO DIAGNOSTICS MARKET OVERVIEW
    4.2 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2020)
    4.3 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    4.4 GEOGRAPHIC MIX: IN VITRO DIAGNOSTICS MARKET
    4.5 IN VITRO DIAGNOSTICS MARKET: DEVELOPED VS. DEVELOPING MARKETS

5 MARKET OVERVIEW (Page No. - 70)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
          FIGURE 25 IN VITRO DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,  AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising geriatric population and subsequent growth in the prevalence of chronic and infectious diseases
                                TABLE 3 ESTIMATED INCREASE IN THE GERIATRIC POPULATION, BY REGION (2019–2050)
                                FIGURE 26 CHINA: NUMBER OF PEOPLE WITH DIABETES MELLITUS,  2000–2045 (IN MILLIONS)
                    5.2.1.2 Shift from centralized to point-of-care testing
                    5.2.1.3 Growing awareness and initiatives to increase healthcare accessibility in developing countries
                    5.2.1.4 Changing technological landscape
                                TABLE 4 IN VITRO DIAGNOSTICS MARKET: RECENT PRODUCT LAUNCHES
           5.2.2 RESTRAINTS
                    5.2.2.1 Unfavorable reimbursement scenario
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Development of disease-specific biomarkers and tests
                                TABLE 5 CANCER BIOMARKERS AND USES IN CLINICAL PRACTICE
                    5.2.3.2 Growing significance of companion diagnostics
                    5.2.3.3 Growth opportunities in emerging countries
                                sFIGURE 27 ANNUAL PER CAPITA HEALTH EXPENDITURE IN DEVELOPING COUNTRIES,  2019 (USD MILLION)
           5.2.4 CHALLENGES
                    5.2.4.1 Changing regulatory landscape in the EU
                                FIGURE 28 IVDR: KEY AREAS OF IMPACT
                    5.2.4.2 Operational barriers faced in conducting diagnostic tests

6 INDUSTRY INSIGHTS (Page No. - 78)
    6.1 INDUSTRY TRENDS
           6.1.1 AUTOMATION OF CLINICAL LABORATORY TECHNIQUES
           6.1.2 MICROFLUIDICS-BASED POC AND LAB-ON-A-CHIP DIAGNOSTIC DEVICES FOR LABORATORY TESTING
           6.1.3 GROWING NUMBER OF REAGENT RENTAL AGREEMENTS
    6.2 PORTER’S FIVE FORCES ANALYSIS
          TABLE 6 PORTER’S FIVE FORCES ANALYSIS: IN VITRO DIAGNOSTICS MARKET
           6.2.1 INTENSITY OF COMPETITIVE RIVALRY
           6.2.2 BARGAINING POWER OF SUPPLIERS
           6.2.3 BARGAINING POWER OF BUYERS
           6.2.4 THREAT OF NEW ENTRANTS
           6.2.5 THREAT FROM SUBSTITUTES
    6.3 REGULATORY ANALYSIS
           6.3.1 US
                    TABLE 7 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES
                    FIGURE 29 US: REGULATORY PROCESS FOR IVD DEVICES
           6.3.2 CANADA
                    FIGURE 30 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA
           6.3.3 EUROPE
                    TABLE 8 EUROPE: CLASSIFICATION OF IVD DEVICES
                    FIGURE 31 EUROPE: IVDR TIMELINE
           6.3.4 JAPAN
                    FIGURE 32 REGULATORY PROCESS FOR IVD DEVICES IN JAPAN
                    TABLE 9 JAPAN: CLASSIFICATION OF IVD REAGENTS
                    TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           6.3.5 CHINA
                    TABLE 11 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           6.3.6 INDIA
                    FIGURE 33 INDIA: REGULATORY PROCESS FOR IVD DEVICES
           6.3.7 INDONESIA
                    TABLE 12 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
           6.3.8 RUSSIA
                    TABLE 13 RUSSIA: CLASSIFICATION OF IVD DEVICES
           6.3.9 SAUDI ARABIA
                    TABLE 14 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           6.3.10 MEXICO
                    FIGURE 34 MEXICO: REGULATORY PROCESS FOR IVD DEVICES
                     TABLE 15 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           6.3.11 BRAZIL
                     FIGURE 35 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
           6.3.12 SOUTH KOREA
                     TABLE 16 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    6.4 PATENT ANALYSIS
          FIGURE 36 TOP PATENT OWNERS AND APPLICANTS: IN VITRO DIAGNOSTICS MARKET (JANUARY 2011–DECEMBER 2021)
          FIGURE 37 PATENT ANALYSIS: IN VITRO DIAGNOSTICS MARKET  (JANUARY 2011–DECEMBER 2021)
    6.5 TRADE ANALYSIS
           6.5.1 TRADE ANALYSIS FOR DIAGNOSTICS AND LABORATORY REAGENTS
                    TABLE 17 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY  2016–2020 (USD MILLION)
                    TABLE 18 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY  2016–2020 (TONS)
    6.6 ECOSYSTEM ANALYSIS
          FIGURE 38 ECOSYSTEM ANALYSIS: IN VITRO DIAGNOSTICS MARKET
    6.7 VALUE CHAIN ANALYSIS
          FIGURE 39 VALUE CHAIN ANALYSIS: IN VITRO DIAGNOSTICS MARKET
    6.8 SUPPLY CHAIN ANALYSIS
          FIGURE 40 SUPPLY CHAIN ANALYSIS: IN VITRO DIAGNOSTICS MARKET
    6.9 COVID-19 IMPACT ANALYSIS
           6.9.1 COVID-19 HEALTH ASSESSMENT
           6.9.2 COVID-19 ECONOMIC ASSESSMENT
           6.9.3 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
                    FIGURE 41 CRITERIA IMPACTING THE GLOBAL ECONOMY
           6.9.4 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE IN VITRO DIAGNOSTICS MARKET
                    FIGURE 42 COVID-19 IMPACT ON GLOBAL IN VITRO DIAGNOSTICS MARKET
                    FIGURE 43 ROCHE DIAGNOSTICS: IMPACT OF COVID-19
                    FIGURE 44 ABBOTT LABORATORIES, INC.: IMPACT OF COVID-19
    6.10 PRICING ANALYSIS
          TABLE 19 AVERAGE SELLING PRICE (USD): IMMUNOASSAY ANALYZERS
          TABLE 20 AVERAGE SELLING PRICE (USD): LATERAL FLOW ANALYZERS
          TABLE 21 AVERAGE SELLING PRICE (USD): MOLECULAR DIAGNOSTICS
    6.11 TECHNOLOGY ANALYSIS
           6.11.1 KEY TECHNOLOGIES: IN VITRO DIAGNOSTICS MARKET
           6.11.2 ADJACENT TECHNOLOGIES: IN VITRO DIAGNOSTICS MARKET
    6.12 ADJACENT MARKET ANALYSIS
           FIGURE 45 MICROFLUIDICS MARKET: MARKET OVERVIEW
    6.13 CASE STUDY
           FIGURE 46 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOUR  IN INDIA

7 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 105)
    7.1 INTRODUCTION
          TABLE 22 IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
    7.2 REAGENTS & KITS
           7.2.1 TECHNOLOGICAL ADVANCES LIKE RAPID DIAGNOSTICS ARE EXPECTED TO BOOST THE GROWTH OF THIS SEGMENT
                    TABLE 23 IVD REAGENTS & KITS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 24 IVD REAGENTS & KITS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
    7.3 INSTRUMENTS
          TABLE 25 IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 26 IVD INSTRUMENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
          TABLE 27 IVD INSTRUMENTS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           7.3.1 FULLY AUTOMATED INSTRUMENTS
                    7.3.1.1 Rising incidence of various diseases and the increasing need to process heavy sample load to drive the market growth
                                TABLE 28 FULLY AUTOMATED IVD INSTRUMENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.3.2 SEMI-AUTOMATED INSTRUMENTS
                    7.3.2.1 Compact design and cost-effectiveness over automated analyzers are expected to increase the market growth of this segment
                    TABLE 29 SEMI-AUTOMATED IVD INSTRUMENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.3.3 OTHER INSTRUMENTS
                    TABLE 30 OTHER IVD INSTRUMENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.4 DATA MANAGEMENT SOFTWARE
           7.4.1 NEED FOR LABORATORY AUTOMATION DRIVES MARKET GROWTH
                    TABLE 31 KEY DATA MANAGEMENT SOFTWARE SOLUTIONS AVAILABLE IN THE MARKET
                    TABLE 32 IVD DATA MANAGEMENT SOFTWARE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 33 IVD DATA MANAGEMENT SOFTWARE MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
    7.5 SERVICES
           7.5.1 GROWING COMPETITIVENESS AND THE INCREASING NEED TO OFFER VALUE-ADDED SERVICES TO BOOST THE MARKET GROWTH
                    TABLE 34 IVD SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 35 IVD SERVICES MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)

8 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 118)
    8.1 INTRODUCTION
          TABLE 36 IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
    8.2 IMMUNOASSAY/IMMUNOCHEMISTRY
          TABLE 37 IMMUNOASSAY/IMMUNOCHEMISTRY ANALYZERS AVAILABLE IN THE MARKET
          TABLE 38 IVD MARKET FOR IMMUNOASSAY/IMMUNOCHEMISTRY, BY COUNTRY,  2019–2026 (USD MILLION)
          TABLE 39 IVD MARKET FOR IMMUNOASSAY/IMMUNOCHEMISTRY, BY TYPE, 2019–2026 (USD MILLION)
           8.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS
                    TABLE 40 ELISA ANALYZERS AVAILABLE IN THE MARKET
                    TABLE 41 ELISA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 42 ELISA MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    8.2.1.1 Chemiluminescence immunoassays
                               8.2.1.1.1 CLIAs hold the largest share of the ELISA market
                                              TABLE 43 CHEMILUMINESCENCE IMMUNOASSAY SYSTEMS AVAILABLE IN THE MARKET
                                              TABLE 44 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    8.2.1.2 Fluorescence immunoassays
                               8.2.1.2.1 Rapid processing, high sensitivity, and low cost have driven the adoption of FIAs
                                              TABLE 45 FLUORESCENCE IMMUNOASSAY SYSTEMS AVAILABLE IN THE MARKET
                                              TABLE 46 FLUORESCENCE IMMUNOASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    8.2.1.3 Colorimetric immunoassays
                               8.2.1.3.1 Despite widespread use, demand for colorimetric immunoassays has declined due to low sensitivity
                                              TABLE 47 COLORIMETRIC IMMUNOASSAY SYSTEMS AVAILABLE IN THE MARKET
                                              TABLE 48 COLORIMETRIC IMMUNOASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           8.2.2 RADIOIMMUNOASSAYS
                    8.2.2.1 Small sample volumes, rapid processing times offset by high cost and potential health hazards
                                TABLE 49 RADIOIMMUNOASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           8.2.3 RAPID TESTS
                    8.2.3.1 COVID-19 pandemic drove demand for rapid tests
                                TABLE 50 RAPID TESTS AVAILABLE IN THE MARKET
                                TABLE 51 RAPID TESTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           8.2.4 WESTERN BLOTTING
                    8.2.4.1 Western blotting is the gold standard for result validation
                                TABLE 52 WESTERN BLOTTING SYSTEMS AVAILABLE IN THE MARKET
                                TABLE 53 WESTERN BLOTTING MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           8.2.5 ENZYME-LINKED IMMUNOSPOT ASSAYS
                    8.2.5.1 High sensitivity, functionality, and adaptability support the growth of ELISPOT
                                TABLE 54 ELISPOT ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    8.3 CLINICAL CHEMISTRY
          TABLE 55 CLINICAL CHEMISTRY ANALYZERS FOR HIGH AND MID-VOLUME LABORATORIES
          TABLE 56 CLINICAL CHEMISTRY ANALYZERS FOR LOW-VOLUME LABORATORIES
          TABLE 57 BLOOD GAS ANALYZERS AVAILABLE IN THE MARKET
          TABLE 58 IVD MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2019–2026 (USD MILLION)
          TABLE 59 CLINICAL CHEMISTRY MARKET, BY TYPE, 2019–2026 (USD MILLION)
           8.3.1 BASIC METABOLIC PANELS
                    8.3.1.1 Basic metabolic panels hold the largest share of the clinical chemistry market
                                TABLE 60 BASIC METABOLIC PANELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           8.3.2 LIVER PANELS
                    8.3.2.1 Growing liver disease burden and alcohol consumption driving market growth
                                TABLE 61 LIVER PANELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           8.3.3 RENAL PROFILES
                    8.3.3.1 Rising kidney disease prevalence ensures demand for renal profiles
                                TABLE 62 RENAL PROFILES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           8.3.4 LIPID PROFILES
                    8.3.4.1 Growth in CVD caseload supports the adoption of lipid panels
                                TABLE 63 LIPID PROFILES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           8.3.5 THYROID FUNCTION PANELS
                    8.3.5.1 Rising awareness and incidence of thyroid diseases drive the market
                                TABLE 64 THYROID FUNCTION PANELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           8.3.6 ELECTROLYTE PANELS
                    8.3.6.1 Focus on preventive healthcare to favor the market for electrolyte panels
                                TABLE 65 ELECTROLYTE PANELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           8.3.7 SPECIALTY CHEMICAL TESTS
                    8.3.7.1 Includes tests not prescribed regularly, such as protein tests, drugs-of-abuse tests, and therapeutic drug monitoring
                                TABLE 66 SPECIALTY CHEMICAL TESTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    8.4 MOLECULAR DIAGNOSTICS
          TABLE 67 AUTOMATED MOLECULAR DIAGNOSTIC PLATFORMS AVAILABLE IN THE MARKET
          TABLE 68 IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2019–2026 (USD MILLION)
          TABLE 69 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           8.4.1 POLYMERASE CHAIN REACTION
                    8.4.1.1 PCR dominates the molecular diagnostics market
                                TABLE 70 PCR INSTRUMENTS AVAILABLE IN THE MARKET
                                TABLE 71 PCR MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           8.4.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
                    8.4.2.1 Growing popularity of INAAT and NAAT for infectious disease diagnostics to support market growth
                                TABLE 72 INAAT MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           8.4.3 HYBRIDIZATION
                    8.4.3.1 Advanced in hybridization and automation have driven the adoption of hybridization technologies
                                TABLE 73 HYBRIDIZATION MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           8.4.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
                    8.4.4.1 Growing use in personalized medicine and declining costs
                                TABLE 74 NGS INSTRUMENTS AVAILABLE IN THE MARKET
                                TABLE 75 DNA SEQUENCING & NGS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           8.4.5 MICROARRAYS
                    8.4.5.1 Advantages of microarrays—high throughput, resolution, and sensitivity—drive their adoption
TABLE 76 MICROARRAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           8.4.6 OTHER MDX TECHNOLOGIES
                    TABLE 77 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES MARKET, BY COUNTRY,  2019–2026 (USD MILLION)
    8.5 HEMATOLOGY
           8.5.1 INCREASING ADOPTION OF AUTOMATED HEMATOLOGY ANALYZERS IS EXPECTED TO DRIVE THE MARKET GROWTH
                    TABLE 78 HEMATOLOGY ANALYZERS AVAILABLE IN THE MARKET
                    TABLE 79 IVD MARKET FOR HEMATOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
    8.6 MICROBIOLOGY
           8.6.1 RISING PREVALENCE OF INFECTIOUS DISEASES WILL BOOST THE GROWTH OF THIS SEGMENT
                    TABLE 80 MICROBIOLOGY INSTRUMENTS AVAILABLE IN THE MARKET
                    TABLE 81 IVD MARKET FOR MICROBIOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
    8.7 COAGULATION & HEMOSTASIS
           8.7.1 INCREASING NUMBER OF SURGERIES AND GROWING USE OF ANTICOAGULATION THERAPY WILL DRIVE THE MARKET GROWTH FOR THIS SEGMENT
                    TABLE 82 COAGULATION ANALYZERS AVAILABLE IN THE MARKET
                    TABLE 83 POINT-OF-CARE/SELF-MONITORING COAGULATION ANALYZERS AVAILABLE  IN THE MARKET
                    TABLE 84 IVD MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2019–2026 (USD MILLION)
    8.8 URINALYSIS
           8.8.1 RISING PREVALENCE OF DIABETES AND KIDNEY DISORDERS WILL HAVE A POSITIVE IMPACT ON THE GROWTH OF THIS SEGMENT
                    TABLE 85 URINALYSIS INSTRUMENTS AVAILABLE IN THE MARKET
                    TABLE 86 IVD MARKET FOR URINALYSIS, BY COUNTRY, 2019–2026 (USD MILLION)
    8.9 OTHER TECHNOLOGIES
          TABLE 87 BLOOD GLUCOSE TESTING SYSTEMS AVAILABLE IN THE MARKET
          TABLE 88 TISSUE PROCESSORS, EMBEDDERS, MICROTOMES, AND STAINERS AVAILABLE  IN THE MARKET
          TABLE 89 IVD MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2019–2026 (USD MILLION)

9 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION (Page No. - 165)
    9.1 INTRODUCTION
          TABLE 90 IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
    9.2 INFECTIOUS DISEASES
           9.2.1 INFECTIOUS DISEASES ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2020
                    TABLE 91 IVD MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
    9.3 DIABETES
           9.3.1 DIABETES PATIENTS REQUIRE CONSTANT MONITORING
                    TABLE 92 GLOBAL DIABETIC PATIENT POPULATION, 2019 VS. 2030 (MILLION)
                    TABLE 93 IVD MARKET FOR DIABETES, BY COUNTRY, 2019–2026 (USD MILLION)
    9.4 ONCOLOGY
           9.4.1 ADVANCEMENTS IN MOLECULAR DIAGNOSTICS WILL AID THE EARLY DIAGNOSIS OF CANCER
                    TABLE 94 IVD MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
    9.5 CARDIOLOGY
           9.5.1 INCREASING DISEASE BURGEN OF CVD TO DRIVE THE MARKET GROWTH
                    TABLE 95 IVD MARKET FOR CARDIOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
    9.6 DRUG TESTING/PHARMACOGENOMICS
           9.6.1 INCREASING CONSUMPTION OF ILLICIT DRUGS WILL LEAD TO AN INCREASE IN TOXICOLOGY TESTING
                    TABLE 96 IVD MARKET FOR DRUG TESTING/PHARMACOGENOMICS, BY COUNTRY,  2019–2026 (USD MILLION)
    9.7 HIV/AIDS
           9.7.1 HIGH PREVALENCE OF AIDS IS EXPECTED TO BOOST THE MARKET GROWTH
                    TABLE 97 IVD MARKET FOR HIV/AIDS, BY COUNTRY, 2019–2026 (USD MILLION)
    9.8 AUTOIMMUNE DISEASES
           9.8.1 DEVELOPMENT OF NOVEL DISEASE-SPECIFIC BIOMARKERS WILL HAVE A POSITIVE IMPACT ON THE MARKET GROWTH
                    TABLE 98 IVD MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
    9.9 NEPHROLOGY
           9.9.1 INCREASING PREVALENCE OF CHRONIC KIDNEY DISEASES IS EXPECTED TO DRIVE THE MARKET GROWTH FOR THIS SEGMENT
                    TABLE 99 IVD MARKET FOR NEPHROLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
    9.10 OTHER APPLICATIONS
           9.10.1 INCREASING DEMAND FOR SELF-MONITORING KITS IS LIKELY TO HAVE A POSITIVE IMPACT ON THE MARKET GROWTH
                     TABLE 100 IVD MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)

10 IN VITRO DIAGNOSTICS MARKET, BY END USER (Page No. - 177)
     10.1 INTRODUCTION
             TABLE 101 IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.2 HOSPITAL LABORATORIES
             10.2.1 GROWING PATIENT POPULATION AND REIMBURSEMENT POLICIES FOR DIAGNOSTIC TESTS WILL DRIVE THE MARKET GROWTH
                        TABLE 102 IVD MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
     10.3 CLINICAL LABORATORIES
             TABLE 103 IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 104 IVD MARKET FOR CLINICAL LABORATORIES, BY COUNTRY 2019–2026 (USD MILLION)
             10.3.1 LARGE/REFERENCE LABORATORIES
                        10.3.1.1 Rising infectious disease burden and demand for larger testing capacities will drive the growth of this segment
                                      TABLE 105 LARGE/REFERENCE LABORATORIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             10.3.2 MEDIUM-SIZED LABORATORIES
                        10.3.2.1 Increasing use of automated instruments to drive market growth
                                      TABLE 106 MEDIUM-SIZED LABORATORIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             10.3.3 SMALL LABORATORIES
                        10.3.3.1 Increasing adoption of semi-automated instruments and low-end point-of-care devices will boost segment growth
                                      TABLE 107 SMALL LABORATORIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
     10.4 POINT-OF-CARE TESTING CENTERS
             10.4.1 GROWING USE OF POC DEVICES IN HOSPITALS AND CLINICAL LABORATORIES IS EXPECTED TO PROPEL THE GROWTH OF THIS SEGMENT
                        TABLE 108 IVD MARKET FOR POINT-OF-CARE TESTING CENTERS, BY COUNTRY, 2019–2026 (USD MILLION)
     10.5 PATIENTS
             10.5.1 INCREASING ADOPTION OF PATIENT SELF-TESTING KITS TO DRIVE THE MARKET GROWTH
                        TABLE 109 IVD MARKET FOR PATIENTS, BY COUNTRY, 2019–2026 (USD MILLION)
     10.6 ACADEMIC INSTITUTES
             10.6.1 INCREASING INDUSTRY-ACADEMIA COLLABORATIONS FOR PRODUCT DEVELOPMENT SUPPORTS MARKET GROWTH
                        TABLE 110 IVD MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
     10.7 OTHER END USERS
             TABLE 111 IVD MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)

11 IN VITRO DIAGNOSTICS MARKET, BY REGION (Page No. - 188)
     11.1 INTRODUCTION
             TABLE 112 IVD MARKET, BY REGION, 2019–2026 (USD MILLION)
     11.2 NORTH AMERICA
             FIGURE 47 NORTH AMERICA: IVD MARKET SNAPSHOT
             TABLE 113 NORTH AMERICA: IVD MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 114 NORTH AMERICA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
             TABLE 115 NORTH AMERICA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 116 NORTH AMERICA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
             TABLE 117 NORTH AMERICA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
             TABLE 118 NORTH AMERICA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
             TABLE 119 NORTH AMERICA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,  2019–2026 (USD MILLION)
             11.2.1 US
                        11.2.1.1 The US dominates the North American Market
                                      TABLE 120 US: MACROECONOMIC INDICATORS
                                      TABLE 121 US: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                      TABLE 122 US: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 123 US: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                      TABLE 124 US: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 125 US: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
                                      TABLE 126 US: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019–2026 (USD MILLION)
             11.2.2 CANADA
                        11.2.2.1 Increasing prevalence of chronic illness and implementation of favorable government initiatives drive the market in Canada
                                      TABLE 127 CANADA: ESTIMATED PREVALENCE OF DIABETES
                                      TABLE 128 CANADA: MACROECONOMIC INDICATORS
                                      TABLE 129 CANADA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                      TABLE 130 CANADA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 131 CANADA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                      TABLE 132 CANADA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 133 CANADA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
                                      TABLE 134 CANADA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019–2026 (USD MILLION)
     11.3 EUROPE
             TABLE 135 EUROPE: IVD MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 136 EUROPE: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
             TABLE 137 EUROPE: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 138 EUROPE: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
             TABLE 139 EUROPE: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
             TABLE 140 EUROPE: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
             TABLE 141 EUROPE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019–2026 (USD MILLION)
             11.3.1 GERMANY
                        11.3.1.1 Increasing healthcare expenditure to drive the market growth in Germany
                                      TABLE 142 GERMANY: MACROECONOMIC INDICATORS
                                      TABLE 143 GERMANY: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                      TABLE 144 GERMANY: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 145 GERMANY: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                      TABLE 146 GERMANY: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 147 GERMANY: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
                                      TABLE 148 GERMANY: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019–2026 (USD MILLION)
             11.3.2 FRANCE
                        11.3.2.1 Rising R&D Expenditure in France to drive market growth
                                      TABLE 149 FRANCE: MACROECONOMIC INDICATORS
                                      TABLE 150 FRANCE: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                      TABLE 151 FRANCE: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 152 FRANCE: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                      TABLE 153 FRANCE: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 154 FRANCE: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
                                      TABLE 155 FRANCE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019–2026 (USD MILLION)
             11.3.3 UK
                        11.3.3.1 The increasing number of accredited diagnostic laboratories propels market growth for in vitro diagnostics in the UK
                                      TABLE 156 UK: MACROECONOMIC INDICATORS
                                      TABLE 157 UK: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                      TABLE 158 UK: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 159 UK: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                      TABLE 160 UK: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 161 UK: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
                                      TABLE 162 UK: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019–2026 (USD MILLION)
             11.3.4 ITALY
                        11.3.4.1 Adoption of advanced diagnostic technologies to drive market growth in Italy
                                      TABLE 163 ITALY: MACROECONOMIC INDICATORS
                                      TABLE 164 ITALY: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                      TABLE 165 ITALY: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 166 ITALY: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                      TABLE 167 ITALY: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 168 ITALY: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
                                      TABLE 169 ITALY: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019–2026 (USD MILLION)
             11.3.5 SPAIN
                        11.3.5.1 Growth of the geriatric population and rising demand for testing support the market in Spain
                                      TABLE 170 SPAIN: MACROECONOMIC INDICATORS
                                      TABLE 171 SPAIN: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                      TABLE 172 SPAIN: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 173 SPAIN: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                      TABLE 174 SPAIN: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 175 SPAIN: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
                                      TABLE 176 SPAIN: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019–2026 (USD MILLION)
             11.3.6 RUSSIA
                        11.3.6.1 Increasing access to quality healthcare will support market growth in Russia
                                      TABLE 177 RUSSIA: MACROECONOMIC INDICATORS
                                      TABLE 178 RUSSIA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                      TABLE 179 RUSSIA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 180 RUSSIA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                      TABLE 181 RUSSIA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 182 RUSSIA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
                                      TABLE 183 RUSSIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019–2026 (USD MILLION)
             11.3.7 REST OF EUROPE
                        TABLE 184 ROE: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                        TABLE 185 ROE: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 186 ROE: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                        TABLE 187 ROE: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                        TABLE 188 ROE: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
                        TABLE 189 ROE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019–2026 (USD MILLION)
     11.4 ASIA PACIFIC
             FIGURE 48 ASIA PACIFIC: IVD MARKET SNAPSHOT
             TABLE 190 ASIA PACIFIC: IVD MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 191 ASIA PACIFIC: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
             TABLE 192 ASIA PACIFIC: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 193 ASIA PACIFIC: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
             TABLE 194 ASIA PACIFIC: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
             TABLE 195 ASIA PACIFIC: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
             TABLE 196 ASIA PACIFIC: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019–2026 (USD MILLION)
             11.4.1 JAPAN
                        11.4.1.1 Universal healthcare reimbursement policy to drive market growth in Japan
                                      TABLE 197 JAPAN: MACROECONOMIC INDICATORS
                                      TABLE 198 JAPAN: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                      TABLE 199 JAPAN: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 200 JAPAN: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                      TABLE 201 JAPAN: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 202 JAPAN: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
                                      TABLE 203 JAPAN: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019–2026 (USD MILLION)
             11.4.2 CHINA
                        11.4.2.1 Growing public access to modern healthcare and the outbreak of COVID-19 to drive market growth
                                      TABLE 204 CHINA: MACROECONOMIC INDICATORS
                                      TABLE 205 CHINA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                      TABLE 206 CHINA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 207 CHINA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                      TABLE 208 CHINA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 209 CHINA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
                                      TABLE 210 CHINA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019–2026 (USD MILLION)
             11.4.3 INDIA
                        11.4.3.1 Increasing private & public investments in the country’s healthcare system will drive market growth
                                      TABLE 211 INDIA: MACROECONOMIC INDICATORS
                                      TABLE 212 INDIA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                      TABLE 213 INDIA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 214 INDIA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                      TABLE 215 INDIA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 216 INDIA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
                                      TABLE 217 INDIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019–2026 (USD MILLION)
             11.4.4 SOUTH KOREA
                        11.4.4.1 Increased geriatric population coupled with a parallel increase in chronic illnesses to drive the market growth
                                      TABLE 218 SOUTH KOREA: MACROECONOMIC INDICATORS
                                      TABLE 219 SOUTH KOREA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                      TABLE 220 SOUTH KOREA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 221 SOUTH KOREA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                      TABLE 222 SOUTH KOREA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 223 SOUTH KOREA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
                                      TABLE 224 SOUTH KOREA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019–2026 (USD MILLION)
             11.4.5 INDONESIA
                        11.4.5.1 Increasing insurance penetration and rising burden of infectious diseases to drive market growth
                                      TABLE 225 INDONESIA: MACROECONOMIC INDICATORS
                                      TABLE 226 INDONESIA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                      TABLE 227 INDONESIA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 228 INDONESIA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                      TABLE 229 INDONESIA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 230 INDONESIA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
                                      TABLE 231 INDONESIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019–2026 (USD MILLION)
             11.4.6 REST OF ASIA PACIFIC
                        TABLE 232 ROAPAC: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                        TABLE 233 ROAPAC: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 234 ROAPAC: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                        TABLE 235 ROAPAC: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                        TABLE 236 ROAPAC: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
                        TABLE 237 ROAPAC: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,  2019–2026 (USD MILLION)
     11.5 LATIN AMERICA
             TABLE 238 LATIN AMERICA: IVD MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 239 LATIN AMERICA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
             TABLE 240 LATIN AMERICA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 241 LATIN AMERICA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
             TABLE 242 LATIN AMERICA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
             TABLE 243 LATIN AMERICA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
             TABLE 244 LATIN AMERICA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,  2019–2026 (USD MILLION)
             11.5.1 BRAZIL
                        11.5.1.1 Improving healthcare infrastructure in Brazil to drive the growth of the IVD market
                                      TABLE 245 BRAZIL: MACROECONOMIC INDICATORS
                                      TABLE 246 BRAZIL: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                      TABLE 247 BRAZIL: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 248 BRAZIL: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                      TABLE 249 BRAZIL: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 250 BRAZIL: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
                                      TABLE 251 BRAZIL: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019–2026 (USD MILLION)
             11.5.2 MEXICO
                        11.5.2.1 Improving accessibility and affordability of healthcare services to drive market growth for in vitro diagnostics
                                      TABLE 252 MEXICO: MACROECONOMIC INDICATORS
                                      TABLE 253 MEXICO: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                      TABLE 254 MEXICO: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 255 MEXICO: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                      TABLE 256 MEXICO: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 257 MEXICO: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
                                      TABLE 258 MEXICO: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019–2026 (USD MILLION)
             11.5.3 REST OF LATIN AMERICA
                        TABLE 259 ROLA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                        TABLE 260 ROLA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 261 ROLA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                        TABLE 262 ROLA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                        TABLE 263 ROLA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
                        TABLE 264 ROLA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019–2026 (USD MILLION)
     11.6 MIDDLE EAST & AFRICA
             TABLE 265 MIDDLE EAST & AFRICA: IVD MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 266 MIDDLE EAST & AFRICA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
             TABLE 267 MIDDLE EAST & AFRICA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 268 MIDDLE EAST & AFRICA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
             TABLE 269 MIDDLE EAST & AFRICA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
             TABLE 270 MIDDLE EAST & AFRICA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
             TABLE 271 MIDDLE EAST & AFRICA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,  2019–2026 (USD MILLION)
             11.6.1 SAUDI ARABIA
                        11.6.1.1 High incidence of lifestyle diseases coupled with increasing healthcare budget is to drive market growth
                                      TABLE 272 SAUDI ARABIA: MACROECONOMIC INDICATORS
                                      TABLE 273 SAUDI ARABIA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                      TABLE 274 SAUDI ARABIA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 275 SAUDI ARABIA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                      TABLE 276 SAUDI ARABIA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 277 SAUDI ARABIA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
                                      TABLE 278 SAUDI ARABIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019–2026 (USD MILLION)
             11.6.2 REST OF MIDDLE EAST & AFRICA
                        TABLE 279 ROMEA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                        TABLE 280 ROMEA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 281 ROMEA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                        TABLE 282 ROMEA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                        TABLE 283 ROMEA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)
                        TABLE 284 ROMEA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2019–2026 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 270)
     12.1 OVERVIEW
     12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
     12.3 REVENUE SHARE ANALYSIS FOR KEY PLAYERS IN THE IN VITRO DIAGNOSTICS MARKET
     12.4 MARKET SHARE ANALYSIS
             TABLE 285 IN VITRO DIAGNOSTICS MARKET: DEGREE OF COMPETITION
             12.4.1 MARKET SHARE ANALYSIS, BY TECHNOLOGY
                        12.4.1.1 Clinical chemistry
                                      FIGURE 52 CLINICAL CHEMISTRY MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
                        12.4.1.2 Immunochemistry/immunoassay analyzers
                                      FIGURE 53 IMMUNOASSAYS MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
                        12.4.1.3 Microbiology
                                      FIGURE 54 MICROBIOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
                        12.4.1.4 Molecular diagnostics
                                      FIGURE 55 MOLECULAR DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
                        12.4.1.5 Hematology
                                      FIGURE 56 HEMATOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
                        12.4.1.6 Coagulation & hemostasis
                                      FIGURE 57 COAGULATION & HEMOSTASIS MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
                        12.4.1.7 Urinalysis
                                      FIGURE 58 URINALYSIS MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
     12.5 R&D ASSESSMENT OF KEY PLAYERS
     12.6 GEOGRAPHIC REVENUE ASSESSMENT OF KEY PLAYERS
             FIGURE 59 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC REVENUE MIX
     12.7 COMPANY EVALUATION QUADRANT
             12.7.1 STARS
             12.7.2 PERVASIVE PLAYERS
             12.7.3 EMERGING LEADERS
             12.7.4 PARTICIPANTS
                        FIGURE 60 IN VITRO DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX, 2020
     12.8 COMPETITIVE LEADERSHIP MAPPING FOR SMES & START-UPS
             12.8.1 PROGRESSIVE COMPANIES
             12.8.2 DYNAMIC COMPANIES
             12.8.3 STARTING BLOCKS
             12.8.4 RESPONSIVE COMPANIES
                        FIGURE 61 IN VITRO DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX FOR SMES & START-UPS
     12.9 COMPETITIVE BENCHMARKING
             TABLE 286 OVERALL COMPANY FOOTPRINT
             TABLE 287 COMPANY FOOTPRINT: BY PRODUCT AND SERVICE
             TABLE 288 COMPANY FOOTPRINT: BY TECHNOLOGY
             TABLE 289 COMPANY FOOTPRINT: BY APPLICATION
             TABLE 290 COMPANY FOOTPRINT: BY END USER
     12.1 COMPETITIVE SCENARIO
             12.10.1 PRODUCT LAUNCHES & APPROVALS
                        TABLE 291 PRODUCT LAUNCHES & APPROVALS, 2020–2022
             12.10.2 DEALS
                        TABLE 292 DEALS, 2021
             12.10.3 OTHER DEVELOPMENTS
                        TABLE 293 OTHER DEVELOPMENTS, 2021

13 COMPANY PROFILES (Page No. - 292)
(Business overview, Products offered, Recent Developments, MNM view)*
     13.1 KEY PLAYERS
             13.1.1 ROCHE DIAGNOSTICS
                        TABLE 294 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW
                        FIGURE 62 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2020)
                        TABLE 295 PRODUCT LAUNCHES AND APPROVALS
                        TABLE 296 DEALS
             13.1.2 DANAHER CORPORATION
                        TABLE 297 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 63 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
                        TABLE 298 DEALS
             13.1.3 ABBOTT LABORATORIES, INC.
                        TABLE 299 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 64 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
                        TABLE 300 PRODUCT LAUNCHES AND APPROVALS
                        TABLE 301 DEALS
             13.1.4 SIEMENS HEALTHINEERS
                        TABLE 302 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW
                        FIGURE 65 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2021)
                        TABLE 303 PRODUCT LAUNCHES AND APPROVALS
                        TABLE 304 DEALS
                        TABLE 305 OTHER DEVELOPMENTS
             13.1.5 SYSMEX CORPORATION
                        TABLE 306 SYSMEX CORPORATION: BUSINESS OVERVIEW
                        FIGURE 66 SYSMEX CORPORATION: COMPANY SNAPSHOT (2020)
                        TABLE 307 PRODUCT LAUNCHES AND APPROVALS
                        TABLE 308 DEALS
                        TABLE 309 OTHER DEVELOPMENTS
             13.1.6 THERMO FISHER SCIENTIFIC, INC.
                        TABLE 310 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                        FIGURE 67 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)
                        TABLE 311 PRODUCT LAUNCHES AND APPROVALS
                        TABLE 312 DEALS
                        TABLE 313 OTHER DEVELOPMENTS
             13.1.7 BECTON, DICKINSON AND COMPANY
                        TABLE 314 BD: BUSINESS OVERVIEW
                        FIGURE 68 BD: COMPANY SNAPSHOT (2021)
                        TABLE 315 PRODUCT LAUNCHES AND APPROVALS
                        TABLE 316 DEALS
             13.1.8 BIOMÉRIEUX SA
                        TABLE 317 BIOMÉRIEUX SA: BUSINESS OVERVIEW
                        FIGURE 69 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020)
                        TABLE 318 PRODUCT LAUNCHES AND APPROVALS
                        TABLE 319 DEALS
             13.1.9 BIO-RAD LABORATORIES, INC.
                        TABLE 320 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 70 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2020)
                        TABLE 321 PRODUCT LAUNCHES AND APPROVALS
                        TABLE 322 DEALS
             13.1.10 JOHNSON & JOHNSON
                        TABLE 323 JOHNSON & JOHNSON: BUSINESS OVERVIEW
                        FIGURE 71 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2020)
             13.1.11 AGILENT TECHNOLOGIES, INC.
                        TABLE 324 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
                        FIGURE 72 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020)
                        TABLE 325 PRODUCT LAUNCHES AND APPROVALS
                        TABLE 326 DEALS
             13.1.12 QIAGEN N.V.
                        TABLE 327 QIAGEN N.V.: BUSINESS OVERVIEW
                        FIGURE 73 QIAGEN N.V.: COMPANY SNAPSHOT (2020)
                        TABLE 328 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS
                        TABLE 329 DEALS
                        TABLE 330 OTHER DEVELOPMENTS
             13.1.13 QUIDEL CORPORATION
                        TABLE 331 QUIDEL CORPORATION: BUSINESS OVERVIEW
                        FIGURE 74 QUIDEL CORPORATION: COMPANY SNAPSHOT (2020)
                        TABLE 332 PRODUCT LAUNCHES AND APPROVALS
                        TABLE 333 DEALS
                        TABLE 334 OTHER DEVELOPMENTS
             13.1.14 DIASORIN S.P.A.
                        TABLE 335 DIASORIN S.P.A.: BUSINESS OVERVIEW
                        FIGURE 75 DIASORIN S.P.A.: COMPANY SNAPSHOT (2020)
                        TABLE 336 PRODUCT LAUNCHES AND APPROVALS
                        TABLE 337 DEALS
                        TABLE 338 OTHER DEVELOPMENTS
             13.1.15 ILLUMINA, INC.
                        TABLE 339 ILLUMINA, INC.: BUSINESS OVERVIEW
                        FIGURE 76 ILLUMINA, INC.: COMPANY SNAPSHOT (2020)
                        TABLE 340 PRODUCT REGISTRATIONS, LAUNCHES, AND APPROVALS
                        TABLE 341 DEALS
                        TABLE 342 OTHER DEVELOPMENTS
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
     13.2 OTHER PLAYERS
             13.2.1 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC
                        TABLE 343 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: BUSINESS OVERVIEW
                        FIGURE 77 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2020)
             13.2.2 PERKINELMER INC.
                        TABLE 344 PERKINELMER, INC.: BUSINESS OVERVIEW
                        FIGURE 78 PERKINELMER, INC.: COMPANY SNAPSHOT (2020)
             13.2.3 CHEMBIO DIAGNOSTICS, INC.
                        TABLE 345 CHEMBIO DIAGNOSTICS, INC.: BUSINESS OVERVIEW
                        FIGURE 79 CHEMBIO DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2020)
             13.2.4 HOLOGIC, INC.
                        TABLE 346 HOLOGIC, INC.: BUSINESS OVERVIEW
                        FIGURE 80 HOLOGIC, INC.: COMPANY SNAPSHOT (2021)
             13.2.5 SURMODICS, INC.
                        TABLE 347 SURMODICS, INC.: BUSINESS OVERVIEW
                        FIGURE 81 SURMODICS, INC.: COMPANY SNAPSHOT (2020)
             13.2.6 SPEEDX PTY. LTD.
             13.2.7 GENSPEED BIOTECH GMBH
             13.2.8 ACCELERATE DIAGNOSTICS, INC.
             13.2.9 MERCK KGAA
             13.2.10 CARIS LIFE SCIENCES, INC.

14 APPENDIX (Page No. - 417)
     14.1 DISCUSSION GUIDE
     14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     14.3 AVAILABLE CUSTOMIZATIONS
     14.4 RELATED REPORTS
     14.5 AUTHOR DETAILS

This study involved four major approaches in estimating the current in vitro diagnostics market size. Extensive research was conducted to collect information on the market as well as its peer and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the value market. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

This research study involved widespread secondary sources; directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the animal parasiticides market. It was also used to obtain important information about key players, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include CEOs, vice presidents, marketing and sales directors, business development managers, technology and innovation directors of IVD manufacturing companies, key opinion leaders, and suppliers and distributors. Primary sources from the demand side include veterinary hospitals and clinics, research institutes, academic institutions, and contract manufacturing organizations.

Market Size Estimation

The total size of the in vitro diagnostics market was arrived at after data triangulation from four different approaches, as mentioned below.

Approach 1: Revenue Share Analysis

  • Revenues of individual companies were gathered from public sources and databases.
  • Shares of the IVD business of leading players were gathered from secondary sources to the extent available. In certain cases, the share of the IVD business has been ascertained after a detailed analysis of various parameters, including product portfolios, market positioning, selling price, geographic reach, and strength.
  • Individual shares or revenue estimates were validated through expert interviews.

Approach 2: Bottom-up Approach: Supply-side Analysis

  • The size of the IVD market was estimated for the supply-side analysis by obtaining country-level sales data for the IVD segment through various secondary paid and public databases and primary interviews.
  • Wherever feasible, revenue share analysis was also employed to identify segmental market sizes by identifying leading players in respective product categories.
  • Primary participants validated the numbers.

Approach 3: Top-down Approach: Based on Utilization Rate and Adoption Pattern

  • The size of the IVD market was estimated based on value. The global consumption, by volume, was derived using pricing analysis in various regions through authenticated secondary sources.
  • Percentage splits of the subsegments of the IVD market by product, technique, and application were derived through primary and secondary sources.
  • The geographical uptake of various subsegments in the IVD end-user market was also derived.
  • The regional and country-wise markets for subsegments were thereby derived.
  • Primary participants validated the numbers.

Approach 4: Company Presentations

  • The size of the IVD market was obtained from the annual presentations of leading players.
  • The share of diagnostic products in the overall IVD market was obtained from secondary data and validated by primary participants to arrive at the total IVD market.
  • Primary participants validated the numbers.

Approach 5: Primary Interviews

  • As a part of the primary research process, individual respondent insights on the market size and growth were taken during the interview (regional and global, as applicable).
  • All the responses were collated, and a weighted average was taken to derive a probabilistic estimate of the market size and growth rate.

At each point, the assumptions and approaches were validated through industry experts contacted during primary research. Considering the limitations of data available from secondary research, revenue estimates for individual companies (for the overall animal parasiticides market and geographic market assessment) were ascertained based on a detailed analysis of their respective product offerings, geographic reach/strength (direct or through distributors or suppliers), and the shares of the leading players in a particular region or country.

Breakdown of Primary Interviews

A breakdown of the primary respondents for in vitro diagnostics market (supply side) market is provided below:

In-Vitro Diagnostics Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed wherever applicable.

Approach to derive the market size and estimate market growth

The market rankings for leading players were ascertained after a detailed assessment of their revenues from the in vitro diagnostics business using secondary data available through paid and unpaid sources. Owing to data limitations, in certain cases, the revenue share was arrived at after a detailed assessment of the product portfolios of major companies and their respective sales performance. At each point, this data was validated through primary interviews with industry experts.

Objectives of the Study

  • To define, describe, and forecast the in vitro diagnostics (IVD) market based on product & service, technology, application, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and industry-specific challenges)
  • To assess the in vitro diagnostics market with regard to Porter’s five forces, regulatory landscape, the value chain, the supply chain, the ecosystem, patent protection, and the impact of COVID-19
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze the opportunities in the IVD market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the IVD market in five main regions (along with countries)—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players operating in the IVD market and comprehensively analyze their core competencies and market shares
  • To track and analyze competitive developments such as partnerships, agreements, collaborations, acquisitions, expansions, product/technology developments, and product upgrades.

    Available Customizations

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    Product Analysis

    • Product matrix, which gives a detailed comparison of the product portfolios of each company

    Geographic Analysis

    • Further breakdown of the IVD market in the Rest of the Asia Pacific IVD
    • Further breakdown of the IVD market in the Rest of Latin America IVD
    • Further breakdown of the IVD market in the Rest of the Middle East & Africa

    Company Information

    • Detailed analysis and profiling of additional market players (up to 5)
Report Code
MD 3609
Published ON
Mar, 2022
Choose License Type
BUY NOW
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the In vitro Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved